New approvals this week include a $4.25 million gene therapy, a drug that treats hypertension in a new way, a nonsteroidal drug for Duchenne, and an oral drug for aggressive leukemia. The agency has set an action date for resubmitted Lymphir in rare skin cancer, and Celltrion has launched Zymfentra, a subcutaneous form of infliximab.
The health industry is changing rapidly, and organizations that don’t adapt are going the way of the Model T. By offering new solutions and capabilities, successful organizations are supporting their customers with whole-person, full-journey care.
Given the role of patient self-management in diabetes care, there has been significant investment in digital diabetes management solutions.
The results of this week’s poll about whether copay accumulators should be banned.
High-deductible health plans are supposed to make patients smarter shoppers for healthcare services. But result reported in JAMA Network Open today add to the evidence that people with chronic conditions such as diabetes may put off care when deductibles are high, increasing the risk of complications and worsening of the disease.
Although there is a suspected connection between malaria and HIV, no malaria control strategies have been developed specifically for people living with HIV.
Results from the 2024 State of Patient Access report by the PAN Foundation shared that patients with chronic health conditions, in particular, face barriers to accessing quality care due to costs, coverage gaps and social challenges with healthcare professionals (HCPs).
Researchers found that Black and Hispanic dementia patients had the highest Medicare expenditures.
Lenmeldy is the first approved gene therapy to treat children with juvenile metachromatic leukodystrophy, a life-threatening inherited disease of the body’s metabolic system.
About 20 states have moved to ban copay accumulators.
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
The average sickle cell disease patient on Medicare paid $22,600 for care in 2021.
The FDA this week approved a few firsts: the first treatment for NASH and the first CAR-T cell therapy for CLL/SLL. Other approvals include Tevimbra for esophageal cancer; Livmarli for second liver disease indication; and Praluent for children with genetic form of high cholesterol. The FDA also issued a CRL for monthly MS drug. Additionally, Celltrion submitted an application for an interchangeable Xolair biosimilar.
The results of this week’s poll about Medicare cap extension.
Cyberattacks disproportionately affect healthcare organizations. In 2023, the average data breach cost to a healthcare company was $10.93 million, an 8% increase from the previous year.
The study suggests financial barriers are negatively impacting the wellbeing, productivity and healthcare experiences of Americans with employer-sponsored insurance.
Madrigal Pharmaceuticals is pricing Rezdiffra (resmetirom) at wholesale acquisition price of $47,400 per year.
Six airports currently participate in the volunteer COVID detection tests.
Healthcare Ready, a nonprofit organization committed to protecting the U.S. healthcare system against disasters and pandemics, recently concluded an initiative aimed to understand the consequences of the COVID-19 pandemic and other disaster-related threats on the healthcare workforce.
93% of customers are “satisfied” or “very satisfied” with their coverage this year.
CMS says to stay tuned for guidelines that will allow states to better support their Medicare providers.
As women age, hormonal shifts during menopause often bring visible changes in their physical appearance. Cynthia Elliott, M.D., owner and primary practitioner at Skinspirations, shed light on the concept of "menopause makeovers" and how medical aesthetic procedures can address these changes toward women.
The Incyte drug is headed for assessment in a phase 3 trial.
Healthy, plant-based diets saw a 21% decrease in bone fragility.
Wellpoint is the latest to expand mental health services, teaming up with InStride to offer virtual care for children and adolescents with anxiety and obsessive-compulsive order.
The 92-year-old "Star Trek" star said the skin cancer was treated surgically and with immunotherapy. It was apparently the first time he had discussed his melanoma in public.
Patient preference does not decrease even if their usual provider is unavailable.
The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.
Should the Medicare $2,000 per year cap on out-of-pocket costs for prescription drugs be extended to commercial insurance?
No safety signals emerged during the 26-month open label study of Vyjuvek (beremagene geperpavec), a topical gel approved as a treatment for dystrophic epidermolysis bullosa.
